Zhan He Wu

University of Sydney

Dr. Zhan He Wu graduated from Harbin Medical University, China, and received his Master’s degree in 1985 from the same university. He received his Ph.D. degree in 1993 from the University of New South Wales, Australia. Since 1996, he has been working in the field of human genetic disease studies in the Sydney Genome Diagnostics, Western Sydney Genetics Program, The Children’s Hospital Westmead, Affiliated to the University of Sydney, mainly on hematological malignancies such as leukemia and lymphoma, and inherited bone marrow failure syndromes, including Fanconi anemia (it is named as the prone cancer syndrome and paradigm for cancer and aging research). Dr. Zhan He Wu has published more than 60 original articles, more than 60 scientific conference presentations, and five chapters in books. He was granted as a Founding Fellow of Royal College of Pathologist for Australasia in 2011. In the past, he has organized many national scientific conferences. He was invited as the Chair for the Euro-Global Conference on Pediatrics and Neonatology 2018, 13–15, SEP, ROME, and delivered the welcome message as well. He has been involved in medical journal reviewing and editing and invited by nine international journals as a reviewer, associate editor, guest editor, editor, column chair, and so on. Currently, he is editing two professional books in English for a UK publisher: Germline Mutations Associated Leukemia and Rare Diseases.

2books edited

4chapters authored

Latest work with IntechOpen by Zhan He Wu

In the current practice of modern medicine, the treatment of infectious and nutritional disorders is well established. In contrast, currently genetic disorders/diseases and cancer constitute a substantial load in the clinic. The care of genetic-based diseases and cancer has become a major task in medical practices worldwide and it is unprecedented. It will be rare for any family to be entirely free of genetic disease, therefore genetic diseases impose a huge burden upon individuals, families, and societies. Modern medicine is at the crossroads in the new genomic era with the development of more and more modern technologies. Remarkable advances have been well achieved in defining and classifying these genetic-associated diseases. The identification of the genetic landscape of germ line mutations-associated leukemia caused by either inherited gene mutations or syndromes has led to a deep understanding of leukemogenesis, recognition of clinical diagnosis, and translation into clinical practice in its specific management strategies.

Go to the book